The Percentage of Patients Achieving a Response in Mucosal Disease (or Cutaneous Disease if no Mucosal Disease) at 12 Weeks 12 weeks [clinicaltrials_resource:329eba112e9ccbb5204cf08257830edd]
This is a physician global assessment of disease (0=clear; 1=minimal disease; 2=mild disease; 3=moderate disease; 4=severe disease). The subject have a level >=3 at baseline. To be considered a responder, the subject must achieve a level of 0 or 1, or, at least a 2 point improvement in the scale.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
The Percentage of Patients Achieving a Response in Mucosal Disease (or Cutaneous Disease if no Mucosal Disease) at 12 Weeks 12 weeks [clinicaltrials_resource:329eba112e9ccbb5204cf08257830edd]
This is a physician global assessment of disease (0=clear; 1=minimal disease; 2=mild disease; 3=moderate disease; 4=severe disease). The subject have a level >=3 at baseline. To be considered a responder, the subject must achieve a level of 0 or 1, or, at least a 2 point improvement in the scale.
Bio2RDF identifier
329eba112e9ccbb5204cf08257830edd
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:329eba112e9ccbb5204cf08257830edd
measure [clinicaltrials_vocabulary:measure]
The Percentage of Patients Ach ...... o Mucosal Disease) at 12 Weeks
time frame [clinicaltrials_vocabulary:time-frame]
description
This is a physician global ass ...... oint improvement in the scale.
identifier
clinicaltrials_resource:329eba112e9ccbb5204cf08257830edd
title
The Percentage of Patients Ach ...... Disease) at 12 Weeks 12 weeks
@en
type
label
The Percentage of Patients Ach ...... eba112e9ccbb5204cf08257830edd]
@en